- Home
- IDAI vs ONCO Comparison
IDAI vs ONCO Comparison
Compare IDAI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- ONCO
- Stock Information
- Founded
- IDAI 2016
- ONCO 2018
- Country
- IDAI United States
- ONCO United States
- Employees
- IDAI N/A
- ONCO N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- ONCO Health Care
- Exchange
- IDAI Nasdaq
- ONCO Nasdaq
- Market Cap
- IDAI 9.7M
- ONCO 5.8M
- IPO Year
- IDAI N/A
- ONCO 2022
- Fundamental
- Price
- IDAI $2.68
- ONCO $0.40
- Analyst Decision
- IDAI
- ONCO
- Analyst Count
- IDAI 0
- ONCO 0
- Target Price
- IDAI N/A
- ONCO N/A
- AVG Volume (30 Days)
- IDAI 132.9K
- ONCO 9.9M
- Earning Date
- IDAI 03-31-2025
- ONCO 04-10-2025
- Dividend Yield
- IDAI N/A
- ONCO N/A
- EPS Growth
- IDAI N/A
- ONCO N/A
- EPS
- IDAI N/A
- ONCO N/A
- Revenue
- IDAI $2,160,186.00
- ONCO $1,870,605.00
- Revenue This Year
- IDAI N/A
- ONCO N/A
- Revenue Next Year
- IDAI $139.59
- ONCO N/A
- P/E Ratio
- IDAI N/A
- ONCO N/A
- Revenue Growth
- IDAI N/A
- ONCO N/A
- 52 Week Low
- IDAI $0.15
- ONCO $0.32
- 52 Week High
- IDAI $8.96
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- IDAI 41.42
- ONCO 33.18
- Support Level
- IDAI $2.43
- ONCO $0.58
- Resistance Level
- IDAI $3.22
- ONCO $0.70
- Average True Range (ATR)
- IDAI 0.30
- ONCO 0.06
- MACD
- IDAI -0.14
- ONCO -0.01
- Stochastic Oscillator
- IDAI 23.36
- ONCO 0.00
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.